GUÍA TÉCNICA G-BIOF 02: - Instituto de Salud Pública de Chile

guts technique yielding realistic absorption rate. J. Pharm. Sci., 58(10):
1196-1199, 1969
EMEA,1998. (European Agency for the Evaluation of Medicinal
Products), Note for Guidance on the Investigation of Bioavailability and
Bioequivalence. Committee for Proprietary Medicinal Products
(CPMP/EWP/QWP/1401/98)
EMEA, 2001. Note for Guidance on the Investigation of Bioavailability
and Bioequivalence. Committee for Proprietary Medicinal Products
http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf
Fan de Waterbeend H. Fundamental Variables of the Biopharmaceutics
Classification System (BCS: A Commentary). European Journal of
Pharmaceutical Sciences., Vol 7: 1-3, 1998
Farmacopea de los Estados Unidos de América-Formulario Nacional. .
Volumen 1, páginas 303; 586; 600; 638; 886; 1088. The United States
Pharmacopeia Convention Inc, 2007
FDA 1987. Guía para la Industria: Submitting Documentation for the
Stability of Human Drugs and Biologics, USA
FDA. 1987. Guideline on General Principles of Process Validation. US
Food and Drug Administration, Center for Drug Evaluation and
Research, USA
FDA, 1992. Code of Federal Regulations. 21CFR320.1. US Food and
Drug Administration, Department of Health and Human Services. Drugs
for Human Use Bioavailability and Bioequivalence Requirements
FDA, 1993. Guía para inspecciones de laboratorios de Control de
Av. Marathón 1000 – Ñuñoa – Casilla 48 – Santiago – Teléfono: 350 74 77 – Código Postal: 7780050 – www.ispch.cl
G-BIOF-02
56